이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Beximco Pharmaceuticals 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	15.4yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

CEO

Beximco Pharmaceuticals 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Mohammad Nawaz	Chief Financial Officer	15.8yrs	데이터 없음	데이터 없음
S. M. Reza	Chief Operating Officer	15.4yrs	데이터 없음	데이터 없음
Jamal Choudhury	Director of Accounts & Finance	no data	데이터 없음	데이터 없음
Rizvi Kabir	Director of Marketing	no data	데이터 없음	데이터 없음
M. A. Bhuiyan	General Manager of Human Resources	no data	데이터 없음	데이터 없음
Zakaria Chowdhury	Head of Distribution Services & Director of International Marketing	14.8yrs	데이터 없음	데이터 없음
Mohammad Ullah	Company Secretary & Executive Director	no data	데이터 없음	데이터 없음

15.4yrs

평균 재임 기간

경험이 풍부한 관리: BXPHARMA 의 관리팀은 노련하고 경험 (평균 재직 기간 15.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mohammad Ullah	Company Secretary & Executive Director	no data	데이터 없음	데이터 없음
Salman Rahman	Vice Chairman	no data	데이터 없음	2.04% BDT 612.9m
Abu Bakar Rahman	Director	31.8yrs	데이터 없음	데이터 없음
Osman Chowdhury	Director	no data	데이터 없음	데이터 없음
Iqbal Ahmed	Director	39.8yrs	데이터 없음	데이터 없음
Ahmed Sohail Rahman	Chairman	no data	데이터 없음	2.03% BDT 611.5m
Quamrun Ahmed	Non-Executive Director	3.9yrs	데이터 없음	데이터 없음
Mamtaz Ahmed	Independent Non-Executive Director	4.3yrs	데이터 없음	데이터 없음
Reem Shamsuddoha	Non-Executive Director	3.9yrs	데이터 없음	데이터 없음
Md. Hosein Khan	Independent Director	3.8yrs	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: BXPHARMA 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Beximco Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Less than half of directors are independent

Less than half of directors are independent

Beximco Pharmaceuticals Limited Announces Board Changes

Recent updates

Price target increased by 9.3% to ৳168

Third quarter 2024 earnings released: EPS: ৳3.06 (vs ৳2.13 in 3Q 2023)

Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024

Second quarter 2024 earnings released: EPS: ৳3.21 (vs ৳2.77 in 2Q 2023)

Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Upcoming dividend of ৳3.50 per share at 2.4% yield

Full year 2023 earnings released: EPS: ৳10.34 (vs ৳11.48 in FY 2022)

Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Beximco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 19, 2023

Third quarter 2023 earnings released: EPS: ৳2.13 (vs ৳2.47 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ৳2.77 (vs ৳3.84 in 2Q 2022)

Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS misses analyst expectations

Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended 30 June 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to ৳182

Less than half of directors are independent

Now 20% undervalued after recent price drop

Consensus EPS estimates increase by 18%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Beximco Pharmaceuticals Limited Launches First Generic Version of Pfizer's COVID-19 Treatment Paxlovid

Upcoming dividend of ৳3.50 per share

Full year 2021 earnings released: EPS ৳11.49 (vs ৳7.88 in FY 2020)

Third quarter 2021 earnings released: EPS ৳3.28 (vs ৳2.02 in 3Q 2020)

Investor sentiment improved over the past week

Beximco Pharmaceuticals Limited Updates on the Supply of Covid-19 Vaccine

Second quarter 2021 earnings released: EPS ৳2.54 (vs ৳1.93 in 2Q 2020)

Analysts increase EPS estimates to ৳10.32

Price target raised to ৳114

Beximco Pharmaceuticals Limited Announces Board Changes

Beximco Pharmaceuticals Limited Provides Update on the Supply of COVID-19 Vaccine

Beximco Pharmaceuticals Limited Confirms Quamrun Naher Ahmed and Reem H. Shamsuddoha as Non-Executive Directors

Investor sentiment improved over the past week

New 90-day high: ৳170

New 90-day high: ৳159

Beximco Pharmaceuticals Limited Announces Directors Appointments

New 90-day high: ৳148

Price target raised to ৳113

New 90-day high: ৳148

Price target raised to ৳116

New 90-day high: ৳145

First quarter 2021 earnings released: EPS ৳2.65

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ৳8.67

Beximco Pharmaceuticals Limited Enters into A Memorandum of Understanding for the Supply and Distribution of 30 Million Doses of the Oxford University/AstraZeneca SARS-CoV-2 Vaccine, AZD1222, in Bangladesh

New 90-day high: ৳127

Beximco Pharmaceuticals Limited Receives US Food and Drug Administration (Fda) Approval for Antiarryhtmic Drug Flecainide

Price target raised to ৳105

New 90-day high - ৳116

CEO

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령